EUCTR2013-005542-11-FR进行中（未招募）1 期
A Randomized, Double-Blind Study Evaluating the Efficacy, Safety and Immunogenicity of ABP 798 Compared with Rituximab in Subjects with CD20 Positive B-Cell Non-Hodgkin Lymphoma (NHL) - Not Applicable
Amgen Inc.0 个研究点目标入组 250 人开始时间: 2014年7月31日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 250
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Males and females = 18 and < 80 years of age
- •Histological confirmed, Grade 1, 2 follicular B-cell NHL expressing CD20 within 3 months before randomization
- •Stage 2, 3, or 4 (per Cotswold’s Modification of Ann Arbor Staging System) with measurable disease (per International Working Group)
- •subjects must have a baseline scan (computed tomography [CT]) of the neck (if palpable lymph node > 1.0 cm), chest, abdomen, and pelvis to assess disease burden within 28 days before randomization
- •subjects must have had a baseline bone marrow biopsy within 3 months before randomization
- •Low tumor burden based on the Groupe d'Etudes des Lymphomes Folliculaires (GELF) criteria
- •Blood counts:
- •absolute neutrophil count (ANC) = 1.5 x 109 g/dL (1,500/µL)
- •lymphocytes < 1.5 x the upper limit of normal (ULN)
- •platelets = 100 x 109 g/dL (100,000/µL)
- •hemoglobin = 10.0 g/dL
- •Adequate hepatic function as defined by:
- •aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2 × ULN
- •Adequate renal function as defined by creatinine < 1.5 x ULN or estimated creatinine clearance = 50 mL/min calculated by the Cockcroft-Gault method
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 125
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 125
排除标准
- •Diffuse large cell component and/or Grade 3 follicular NHL
- •History or known presence of central nervous system metastases
- •Malignancy other than NHL within 5 years (except treated in-situ cervical cancer, or squamous or basal cell carcinoma of the skin)
- •Any of the following before randomization:
- •clinically significant cardiovascular disease (including myocardial infarction, unstable angina, symptomatic congestive heart failure [New York Heart Association = Class III], serious uncontrolled cardiac arrhythmia);
- •peripheral vascular disease, cerebrovascular accident, or transient ischemic attack in the previous 6 months
- •Medically uncontrolled hypertension or systolic blood pressure > 160 mmHg or diastolic blood pressure > 100 mmHg
- •Known active or history of active tuberculosis (TB)
- •Positive for hepatitis B surface antigen, hepatitis B core antibody, or hepatitis C virus antibody at screening
- •Known to be human immunodeficiency virus positive
- •Recent infection requiring a course of systemic anti-infective agents that was completed = 7 days before randomization (with the exception of uncomplicated urinary tract infection)
- •Subject is currently enrolled in or has not yet completed at least 30 days or 5 half-lives (whichever is longer) since ending other investigational device or drug study(s), including vaccines, or subject is receiving other investigational agent(s)
- •Previous use of either commercially available or investigational chemotherapy, biological, or immunological therapy for NHL (including rituximab or biosimilar rituximab, or other anti-CD20 treatments)
- •Live vaccines within 28 days prior to the first dose of IP
- •History of neurologic symptoms suggestive of central nervous system demyelinating disease
- •Woman of childbearing potential who is pregnant or is breastfeeding
- •Woman of childbearing potential who does not consent to use highly effective methods of birth control (eg, true abstinence, sterilization, birth control pills, Depo Provera injections, or contraceptive implants) during treatment and for an additional 12 months after the last administration of the protocol specified-treatment
- •Man with a partner of childbearing potential who does not consent to use highly effective methods of birth control (eg, true abstinence, vasectomy, or a condom in combination with hormonal birth control or barrier methods used by the woman) during treatment and for an additional 12 months after the last administration of the protocol specified treatment
- •Subject has known sensitivity to any of the products to be administered during the study, including mammalian cell derived drug products
研究者
相似试验
进行中（未招募）
1 期
The trial is designed to determine the efficacy and safety of ABP 798 compared with rituximab in subjects with CD 20 positive B-cell non Hodgkin lymphomaEUCTR2013-005542-11-GRAmgen Inc.250
进行中（未招募）
1 期
The trial is designed to determine the efficacy and safety of ABP 798 compared with rituximab in subjects with CD 20 positive B-cell non Hodgkin lymphomaCD20 positive B-cell non-Hodgkin lymphomaMedDRA version: 17.0Level: HLGTClassification code 10025320Term: Lymphomas non-Hodgkin's B-cellSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2013-005542-11-ESAmgen Inc.250
进行中（未招募）
2 期
A clinical study to evaluate the efficacy, safety and tolerability of XtraBosTM (Boswellia Serrata Extract) in patients with osteoarthritis associated with hypertension or neuropathic pain, or sleep disorder.CTRI/2023/07/055345Dr Willmar Schwabe India Pvt Ltd
进行中（未招募）
不适用
The trial is designed to determine the efficacy and safety of ABP 798 compared with rituximab in subjects with CD 20 positive B-cell non Hodgkin lymphomaEUCTR2013-005542-11-ITAmgen Inc.250
进行中（未招募）
1 期
The trial is designed to determine the efficacy and safety of ABP 798 compared with rituximab in subjects with CD 20 positive B-cell non Hodgkin lymphomaCD20 positive B-cell non-Hodgkin lymphomaMedDRA version: 20.0 Level: HLGT Classification code 10025320 Term: Lymphomas non-Hodgkin's B-cell System Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2013-005542-11-BGAmgen Inc.250